1.60
+0(+0.00%)
Currency In USD
| Previous Close | 1.6 |
| Open | 1.61 |
| Day High | 1.68 |
| Day Low | 1.53 |
| 52-Week High | 20 |
| 52-Week Low | 1.53 |
| Volume | 239,705 |
| Average Volume | 524,972 |
| Market Cap | 31.18M |
| PE | -0.38 |
| EPS | -4.22 |
| Moving Average 50 Days | 3.59 |
| Moving Average 200 Days | 6.93 |
| Change | 0 |
If you invested $1000 in Annovis Bio, Inc. (ANVS) since IPO date, it would be worth $166.84 as of March 12, 2025 at a share price of $1.6. Whereas If you bought $1000 worth of Annovis Bio, Inc. (ANVS) shares 3 years ago, it would be worth $129.03 as of March 12, 2025 at a share price of $1.6.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Annovis to Host Patients’ Live Forum on February 27, 2025
GlobeNewswire Inc.
Feb 19, 2025 1:30 PM GMT
MALVERN, Pa., Feb. 19, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s disease (AD
Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 07, 2025 1:00 PM GMT
MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease
GlobeNewswire Inc.
Feb 05, 2025 1:00 PM GMT
MALVERN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s